{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis%2C+Relapsing+Forms",
    "query": {
      "condition": "Multiple Sclerosis, Relapsing Forms"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 69,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis%2C+Relapsing+Forms&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T20:52:31.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02230969",
      "title": "Plegridy Observational Program",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "peginterferon beta-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1208,
      "start_date": "2014-11-12",
      "completion_date": "2022-01-20",
      "has_results": false,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 50,
      "location_summary": "Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "California City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230969"
    },
    {
      "nct_id": "NCT03737851",
      "title": "A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "elezanumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 208,
      "start_date": "2018-12-11",
      "completion_date": "2021-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Hanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737851"
    },
    {
      "nct_id": "NCT00464074",
      "title": "Evaluation of Natalizumab for thE Relief of MS Associated FatiGue",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 89,
      "start_date": "2007-08-01",
      "completion_date": "2010-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464074"
    },
    {
      "nct_id": "NCT02601885",
      "title": "A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ABT-555",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-10-18",
      "completion_date": "2018-04-20",
      "has_results": false,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 8,
      "location_summary": "Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601885"
    },
    {
      "nct_id": "NCT02201108",
      "title": "Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 166,
      "start_date": "2014-07-16",
      "completion_date": "2024-07-29",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 4,
      "location_summary": "Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02201108"
    },
    {
      "nct_id": "NCT01158183",
      "title": "Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "BAY86-5046_Interferon-beta-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 226,
      "start_date": "2007-07",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2010-07-08",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 27,
      "location_summary": "Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more",
      "locations": [
        {
          "city": "Many Locations",
          "state": "Alabama"
        },
        {
          "city": "Many Locations",
          "state": "California"
        },
        {
          "city": "Many Locations",
          "state": "Colorado"
        },
        {
          "city": "Many Locations",
          "state": "Florida"
        },
        {
          "city": "Many Locations",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158183"
    },
    {
      "nct_id": "NCT01591551",
      "title": "NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Natalizumab (Tysabri)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Health Care, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2012-03",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 3,
      "location_summary": "Patchogue, New York • High Point, North Carolina • Portland, Oregon",
      "locations": [
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591551"
    },
    {
      "nct_id": "NCT02410278",
      "title": "Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "montelukast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2015-03-12",
      "completion_date": "2017-04-27",
      "has_results": true,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 50,
      "location_summary": "Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410278"
    },
    {
      "nct_id": "NCT06526000",
      "title": "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis",
        "Clinically Isolated Syndrome",
        "Relapsing-remitting Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2022-10-11",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06526000"
    },
    {
      "nct_id": "NCT05028634",
      "title": "Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Tetanus, diphtheria, and acellular pertussis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal polysaccharide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Seasonal influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 63,
      "start_date": "2021-11-11",
      "completion_date": "2023-11-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-07-22T20:52:31.455Z",
      "location_count": 29,
      "location_summary": "Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Southington",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028634"
    }
  ]
}